Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.
Bristol Myers Squibb (BMY) is up more than +1% after gaining FDA approval for its Cobenfy drug to treat patients with schizophrenia. Amgen (AMGN) is up more than +1% after Cantor Fitzgerald initiated ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
Highlights,Geron Corporation, a penny stock in the Healthcare sector, focuses on developing treatments for blood cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback